- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: galapagos.
Displaying page 1 of 2.
EudraCT Number: 2019-001279-34 | Sponsor Protocol Number: GLPG1690-CL-206 | Start Date*: 2019-08-20 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis | |||||||||||||
Medical condition: Systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000719-30 | Sponsor Protocol Number: GLPG0634-CL-341 | Start Date*: 2022-08-30 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, controlled, multi-center study to evaluate the efficacy and safety of dose de-escalation of orally administered filgotinib in subjects with ulcerative colitis in clinica... | |||||||||||||
Medical condition: ulcerative colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) CZ (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001817-33 | Sponsor Protocol Number: GLPG1690-CL-204 | Start Date*: 2019-01-14 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic... | |||||||||||||
Medical condition: Systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000659-11 | Sponsor Protocol Number: GLPG3970-CL-210 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000545-52 | Sponsor Protocol Number: GLPG0634-CL-225 | Start Date*: 2017-10-06 | |||||||||||
Sponsor Name:Galapagos Nv | |||||||||||||
Full Title: A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis | |||||||||||||
Medical condition: Psoriatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001405-87 | Sponsor Protocol Number: GLPG1690-CL-303 | Start Date*: 2018-12-20 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for mi... | |||||||||||||
Medical condition: Idiopatic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002763-34 | Sponsor Protocol Number: GS-US-419-3896 | Start Date*: 2017-02-08 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease | |||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Completed) SE (Completed) GR (Completed) PT (Completed) SK (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) NL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001142-10 | Sponsor Protocol Number: MOR106-CL-201 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:Galapagos N.V. | |||||||||||||
Full Title: A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with mo... | |||||||||||||
Medical condition: atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002837-31 | Sponsor Protocol Number: GLPG2222-CL-201 | Start Date*: 2016-12-02 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (cla... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001406-29 | Sponsor Protocol Number: GLPG1690-CL-304 | Start Date*: 2019-01-28 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for mi... | |||||||||||||
Medical condition: Idiopatic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003292-30 | Sponsor Protocol Number: GLPG1837-CL-202 | Start Date*: 2016-01-18 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation. | |||||||||||||
Medical condition: Cystic fibrosis with the S1251N mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004157-41 | Sponsor Protocol Number: GLPG1690CL202 | Start Date*: 2016-03-21 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Adm... | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003298-22 | Sponsor Protocol Number: GLPG3970-CL-207 | Start Date*: 2021-01-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ... | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) GR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003630-25 | Sponsor Protocol Number: GS-US-417-0304 | Start Date*: 2017-06-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Ongoing) BE (Ongoing) CZ (Ongoing) DE (Ongoing) PL (Ongoing) ES (Completed) BG (Ongoing) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003521-21 | Sponsor Protocol Number: GLPG2737-CL-203 | Start Date*: 2020-01-20 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, fol... | |||||||||||||
Medical condition: Autosomal dominant polycystic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003291-77 | Sponsor Protocol Number: GLPG1837-CL-201 | Start Date*: 2016-02-02 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation | |||||||||||||
Medical condition: Cystic fibrosis with the G551D mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002181-42 | Sponsor Protocol Number: GLPG2737-CL-202 | Start Date*: 2017-10-27 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000658-83 | Sponsor Protocol Number: GLPG3970-CL-209 | Start Date*: 2020-10-21 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects ... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004477-40 | Sponsor Protocol Number: GLPG2222-CL-202 | Start Date*: 2017-05-26 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004302-18 | Sponsor Protocol Number: GLPG1205-CL-220 | Start Date*: 2018-06-18 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SE (Completed) FR (Completed) BG (Completed) FI (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.